Zobrazeno 1 - 10
of 446
pro vyhledávání: '"Pemafibrate"'
Autor:
Jean-Charles Fruchart, Jamila Fruchart-Najib, Shizuya Yamashita, Peter Libby, Koutaro Yokote, Tatsuhiko Kodama, Yohei Tomita, Paul M. Ridker, Michel P. Hermans, Alberto Zambon
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-8 (2024)
Abstract The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, indicators suggesting therapeutic
Externí odkaz:
https://doaj.org/article/59123db750ae4b5c876f8af1f2d916c1
Autor:
Hiroyuki Shinozaki, Shiori Kawai, Mami Gamo-Kawasaki, Ayano Takei, Kyoko Tsujikado, Kazunori Fukuda, Mototaka Yamauchi, Kenji Hara, Takafumi Tsuchiya, Kohzo Takebayashi, Koshi Hashimoto
Publikováno v:
Endocrine Journal, Vol 71, Iss 9, Pp 907-924 (2024)
Fibroblast growth factor (FGF) 21, a hormone produced by the liver, improves glucose and lipid metabolism. We recently demonstrated that the FGF21 gene (Fgf21) underwent DNA demethylation in the mouse liver via peroxisome proliferator-activated recep
Externí odkaz:
https://doaj.org/article/43428d5deb89468386f0725b530c53c5
Autor:
Takanobu Iwadare, Takefumi Kimura, Hideo Kunimoto, Taiki Okumura, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Naoki Tanaka, Takeji Umemura
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
AimShort-term use of pemafibrate (PEM), a selective modulator of peroxisome proliferator-activated receptor alpha, has been reported to improve abnormal liver function in patients with nonalcoholic fatty liver disease with hypertriglyceridemia (HTG-N
Externí odkaz:
https://doaj.org/article/a1f84d912d96457280986941cd66bf83
Autor:
Hiroki Ono, Masanori Atsukawa, Akihito Tsubota, Taeang Arai, Kenta Suzuki, Tetsuyuki Higashi, Michika Kitamura, Kaori Shioda‐Koyano, Tadamichi Kawano, Yuji Yoshida, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Chisa Kondo, Mototsugu Nagao, Masato Iwabu, Katsuhiko Iwakiri
Publikováno v:
JGH Open, Vol 8, Iss 4, Pp n/a-n/a (2024)
Abstract Background and Aim This study aimed to clarify the efficacy and safety of 48‐week pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) complicated by dyslipidemia. Methods A total of 110
Externí odkaz:
https://doaj.org/article/cd543728d12b41028b02332794275195
Autor:
Takeshi Ichikawa, Haruki Oba, Mai Owada, Kazuki Watanabe, Tsubasa Yoshimura, Ayako Fuchigami, Atsushi Nakamura
Publikováno v:
JGH Open, Vol 7, Iss 12, Pp 959-965 (2023)
Abstract Background and Aim In this retrospective study, we evaluated the effects of pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) and hypertriglyceridemia using non‐invasive stiffness‐b
Externí odkaz:
https://doaj.org/article/a4f20904ea4248a7bccc50065f0e2dea
Autor:
Junko Oya, Tomoko Nakagami, Yuichiro Kondo, Aki Katamine, Mika Shimizu, Yukiko Hasegawa, Tetsuya Babazono
Publikováno v:
Tokyo Women's Medical University Journal, Vol 7, Iss 0, Pp 101-108 (2023)
Background: To compare the efficacy and safety of pemafibrate with those of fenofibrate in a real-world setting in patients with hypertriglyceridemia and type 2 diabetes (T2D). Methods: This study included 155 patients with hypertriglyceridemia (>175
Externí odkaz:
https://doaj.org/article/bac49c7903e849349bd63c2e7efbf13e
Publikováno v:
Livers, Vol 3, Iss 4, Pp 562-568 (2023)
Aim: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. Pemafibrate, a selective peroxisome-proliferator-activated receptor α modulator (SPPARMα), has been reported to ameliorate liver function among patien
Externí odkaz:
https://doaj.org/article/d2ce1b280a364a479ae1fd5841269295
Autor:
Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Takahisa Handa, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 15, Iss 1, Pp 1-6 (2023)
Abstract Background Pemafibrate has been reported to ameliorate lipid profiles and liver dysfunction. However, which patients derive benefit from the hepatoprotective effects of pemafibrate is unclear. Methods We conducted a sub-analysis of the PARM-
Externí odkaz:
https://doaj.org/article/5bb4852fbbde4581be2db141350d4fa6
Autor:
Shigeki Kitamura, Naoya Murao, Shoko Yokota, Masaru Shimizu, Tomoyuki Ono, Yusuke Seino, Atsushi Suzuki, Yuko Maejima, Kenju Shimomura
Publikováno v:
BMC Research Notes, Vol 16, Iss 1, Pp 1-8 (2023)
Abstract Objective Insulin secretion is regulated by ATP-sensitive potassium (KATP) channels in pancreatic beta-cells. Peroxisome proliferator-activated receptors (PPAR) α ligands are clinically used to treat dyslipidemia. A PPARα ligand, fenofibra
Externí odkaz:
https://doaj.org/article/16b4b294cf154b6cb024b62b129c2711
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.